Back to Journals » Therapeutics and Clinical Risk Management » Volume 16

Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date

Authors Si S, Teachey DT

Received 28 May 2020

Accepted for publication 24 July 2020

Published 4 August 2020 Volume 2020:16 Pages 705—714

DOI https://doi.org/10.2147/TCRM.S223468

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Professor Garry Walsh


Stephanie Si,1,2 David T Teachey1,2

1Children’s Hospital of Philadelphia, Division of Oncology, Philadelphia, PA, USA; 2Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

Correspondence: Stephanie Si
University of Hawai’i Cancer Center, 701 Ilalo Street, Honolulu, Hawaii 96813, USA
Tel +1 310 266 8480
Email ssi@cc.hawaii.edu

Abstract: Immune-based therapies such as chimeric antigen receptor (CAR)-T-cell therapy have revolutionized the landscape of cancer treatment in recent years. Although this class of therapy has demonstrated impressive clinical efficacy against cancers that were once thought to be incurable, its success is in part limited by unique toxicities which can be severe or even fatal. Cytokine release syndrome (CRS) is the most commonly observed toxicity and occurs as a result of non-antigen specific immune activation. Similar to macrophage activation syndrome (MAS)/hemophagocytic lymphohistiocytosis (HLH), CRS is associated with elevated levels of several cytokines including interleukin-6 (IL-6) that serve as a driver for host immune dysregulation. As a direct anti-cytokine drug, tocilizumab has been a cornerstone in the treatment of CAR-T-associated CRS through its ability to dampen CRS without compromising CAR-T-cell function. However, optimal timing of administration is yet unknown. Here, we review the use of tocilizumab in the management of CAR-T-associated CRS, emphasizing on the clinical efficacy across various CAR constructs and its role in current CRS management algorithms. We also discuss alternative therapies that may be considered for refractory CRS therapy and the use of tocilizumab in the current COVID-19 global pandemic.

Keywords: chimeric antigen receptor-T-cell therapy, cytokine release syndrome, tocilizumab, pediatric

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]